REGN vs RUN · P/E 14, rev $14.34B vs P/E 6.0, rev $2.04B
Regeneron Pharmaceuticals Inc (REGN) versus Sunrun Inc (RUN) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Sunrun Inc (RUN) is a solar company listed on NASDAQ.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported RUN revenue for 2024-12-31 was $2.04B. Net income was -$4.36B. Revenue was down 9.8% from 2023-12-31 to 2024-12-31. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
Not investment advice. Open the REGN and RUN stock pages for the full models.
Not investment advice.